{"ModuleTitle": "Company Description", "CompanyName": "Catalyst Pharmaceuticals, Inc.", "Symbol": "CPRX", "Address": "355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES, Florida, 33134, United States of America", "Phone": "(305) 529-2522", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "We are a biopharmaceutical company focused on developing and commercializing\r\ninnovative therapies for people with rare, debilitating, chronic neuromuscular\r\nand neurological diseases. We are dedicated to making a meaningful impact on the\r\nlives of those suffering from rare diseases, and we believe in putting patients\r\nfirst in everything we do.\r\n\r\nFirdapse\u00ae\r\n\r\nIn October 2012, we licensed the North American rights to Firdapse\u00ae, a\r\nproprietary form of amifampridine phosphate, or chemically known as\r\n3,4-diaminopyridine phosphate. When we acquired the rights to the product, it\r\nhad already been granted orphan drug designation by the FDA for the treatment of\r\npatients with LEMS, a rare and sometimes fatal autoimmune disease characterized\r\nby muscle weakness. Additionally, in August 2013, we were granted \"breakthrough\r\ntherapy designation\" by the FDA for Firdapse\u00ae for the treatment of LEMS.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f03%2f16%2f0001193125-20-075048.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Alicia Grande", "title": "CFO, Treasurer, Principal Accounting Officer & VP"}, {"name": "Gary Ingenito", "title": "Chief Medical Officer"}, {"name": "Patrick J. McEnany", "title": "Chairman, President & Chief Executive Officer"}, {"name": "Stanley Iyadurai", "title": "Vice President-Clinical Development"}, {"name": "Steven R. Miller", "title": "Chief Operating & Scientific Officer"}], "Number_of_employees": [], "Subsidiaries": ["NO INFO"]}